Immunotherapy Global Market - Forecast to 2021

Publishing Date : November, 2015
Report Code : HCPH0101
Price:
Single license $4,500
Site license $6,300
Global license $9,000


Immunotherapy is the treatment given to suppress or amplify the immune response of a person using immunomodulators. The amplification of immune response is called as activation immunotherapy and the suppression of the immune response is called suppression immunotherapy. The global immunotherapeutics market is divided based on the segments, application and geography. Based on the segments, the immunotherapeutics are divided into monoclonal antibodies, vaccines, checkpoint inhibitors and non specific therapies. By application, the immunotherapeutics are divided into oncology, inflammatory disease, CNS and others. There are many cancer types such as lung cancer, melanoma, head and neck cancer, leukemia, colorectal cancer (CRC), lymphoma and others.


Geographical wise North America is the largest market, followed by Europe and Asia-pacific. The APAC regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the immunotherapeutics market. Growth in the Asian market is attributed to rising incidence of target diseases, growing geriatric population and better healthcare initiatives by governments and various private organizations.
 

The immunotherapeutics global market is expected to grow at mid range CAGR to reach $138.9 billion by 2021. The factors driving the growth of this market are increasing incidence of immunological diseases such as cancer, autoimmune diseases, high potency of immunotherapy drugs over small molecule drugs, mutual agreements among the companies for drug development to commercialization, adoption of biological therapies in disease management, increasing importance of CART therapies, market penetration of key players across emerging nations, commercialization and distribution of immunotherapy drugs. In addition to this, emerging Asia Pacific and Latin American countries engaging in immunotherapeutics development and increasing government funding are some of the opportunities that are propelling the growth of the market.  However, the high cost of the drug development process with a threat of failure in the end stage and reimbursement issues are hampering the growth of the market. The threat to the immunotherapeutics market is reimbursement issue.
 

The global immunotherapeutics market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the immunotherapeutics market are AbbVie (U.S.), Amgen (U.S.), Biogen (U.S.), Bristol-Myers Squibb (U.S.), Celgene (U.S.), Johnson & Johnson (U.S.), Merck &Co., Inc (U.S.), Novartis (Switzerland), Pfizer (U.S.) and Roche (Switzerland).

 

The report provides an in depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World (RoW)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING INCIDENCE OF IMMUNOLOGICAL DISEASES SUCH AS CANCER, AUTOIMMUNE AND INFECTIOUS DISEASES
        • 3.3.1.2     HIGH POTENCY OF (ANTIBODIES) OVER SMALL MOLECULE DRUGS
        • 3.3.1.3     MUTUAL AGREEMENTS AMONG COMPANIES FROM DRUG DEVELOPMENT TO COMMERCIALIZATION
        • 3.3.1.4     INCREASING IMPORTANCE OF CART THERAPIES
        • 3.3.1.5     ADOPTION OF BIOLOGICAL THERAPIES IN DISEASE MANAGEMENT
        • 3.3.1.6     EMERGING ASIA PACIFIC AND LATIN AMERICAN COUNTRIES ENGAGED IN THE DEVELOPMENT, COMMERCIALIZATION AND DISTRIBUTION OF IMMUNOTHERAPY DRUGS
        • 3.3.1.7     INCREASING GOVERNMENT FUNDING
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     HIGH COST OF DRUG DEVELOPMENT PROCESS WITH A THREAT OF FAILURE IN END STAGE
        • 3.3.2.2     REIMBURSEMENT ISSUES
    • 3.4     PORTER'S FIVE FORCE ANALYSIS
      • 3.4.1     THREAT OF NEW ENTRANTS
      • 3.4.2     THREAT OF SUBSTITUTES
      • 3.4.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.4.4     BARGAINING POWER OF SUPPLIERS
      • 3.4.5     BARGAINING POWER OF BUYERS
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     CHINA
      • 3.5.4     INDIA
      • 3.5.5     JAPAN
    • 3.6     REIMBURSMENT SCENARIO
    • 3.7     PATENT ANALYSIS
    • 3.8     MARKET SHARE ANALYSIS
  • 4     IMMUNOTHERAPEUTICS GLOBAL MARKET, BY TYPE
    • 4.1     INTRODUCTION
    • 4.2     MONOCLONAL ANTIBODIES
      • 4.2.1     NAKED MONOCLONAL ANTIBODIES
      • 4.2.2     CONJUGATED MONOCLONAL ANTIBODIES
        • 4.2.2.1     RADIO-LABELED ANTIBODIES
        • 4.2.2.2     CHEMO-LABELED ANTIBODIES
      • 4.2.3     BISPECIFIC MONOCLONAL ANTIBODIES
    • 4.3     THERAPEUTIC VACCINES
    • 4.4     CHECKPOINT INHIBITORS
    • 4.5     NON-SPECIFIC IMMUNOTHERAPY
      • 4.5.1     CYTOKINES
      • 4.5.2     IMMUNOMODULATING DRUGS
  • 5     IMMUNOTHERAPEUTICS GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     ONCOLOGY
      • 5.2.1     LUNG CANCER
      • 5.2.2     MELANOMA
      • 5.2.3     HEAD AND NECK CANCER
      • 5.2.4     LEUKEMIA
      • 5.2.5     COLORECTAL CANCER
      • 5.2.6     LYMPHOMA
      • 5.2.7     OTHERS
        • 5.2.7.1     BREAST CANCER
        • 5.2.7.2     MYELOMA
        • 5.2.7.3     BLADDER CANCER
    • 5.3     INFLAMMATION
    • 5.4     CENTRAL NERVOUS SYSTEM
    • 5.5     OTHERS
      • 5.5.1     INFECTIOUS DISEASE
      • 5.5.2     OPHTHALMOLOGY
      • 5.5.3     BONE HEALTH
  • 6     REGIONAL MARKET ANALYSIS
    • 6.1     INTRODUCTION
    • 6.2     NORTH AMERICA
    • 6.3     EUROPE
    • 6.4     ASIA PACIFIC
    • 6.5     REST OF THE WORLD
  • 7     COMPANY DEVELOPMENTS
    • 7.1     INTRODUCTION
      • 7.1.1     AGREEMENTS, COLLABORATIONS & PARTNERSHIPS AS MAJOR GROWTH STRATEGY OF PLAYERS
      • 7.1.2     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES
    • 7.2     APPROVALS
    • 7.3     MERGERS AND ACQUISITIONS
    • 7.4     OTHER DEVELOPMENTS
  • 8     MAJOR PLAYER PROFILES
    • 8.1     ABBVIE, INC.
      • 8.1.1     OVERVIEW
      • 8.1.2     FINANCIALS
      • 8.1.3     PRODUCT PORTFOLIO
      • 8.1.4     KEY DEVELOPMENTS
      • 8.1.5     BUSINESS STRATEGY
      • 8.1.6     SWOT ANALYSIS
    • 8.2     AMGEN, INC.
      • 8.2.1     OVERVIEW
      • 8.2.2     FINANCIALS
      • 8.2.3     PRODUCT PORTFOLIO
      • 8.2.4     KEY DEVELOPMENTS
      • 8.2.5     BUSINESS STRATEGY
      • 8.2.6     SWOT ANALYSIS
    • 8.3     BIOGEN
      • 8.3.1     OVERVIEW
      • 8.3.2     FINANCIALS
      • 8.3.3     PRODUCT PORTFOLIO
      • 8.3.4     KEY DEVELOPMENTS
      • 8.3.5     BUSINESS STRATEGY
      • 8.3.6     SWOT ANALYSIS
    • 8.4     BRISTOL-MYERS SQUIBB
      • 8.4.1     OVERVIEW
      • 8.4.2     FINANCIALS
      • 8.4.3     PRODUCT PORTFOLIO
      • 8.4.4     KEY DEVELOPMENTS
      • 8.4.5     BUSINESS STRATEGY
      • 8.4.6     SWOT ANALYSIS
    • 8.5     CELGENE
      • 8.5.1     OVERVIEW
      • 8.5.2     FINANCIALS
      • 8.5.3     PRODUCT PORTFOLIO
      • 8.5.4     KEY DEVELOPMENTS
      • 8.5.5     BUSINESS STRATEGY
      • 8.5.6     SWOT ANALYSIS
    • 8.6     JOHNSON & JOHNSON
      • 8.6.1     OVERVIEW
      • 8.6.2     FINANCIALS
      • 8.6.3     PRODUCT PORTFOLIO
      • 8.6.4     KEY DEVELOPMENTS
      • 8.6.5     BUSINESS STRATEGY
      • 8.6.6     SWOT ANALYSIS
    • 8.7     MERCK & CO, INC.
      • 8.7.1     OVERVIEW
      • 8.7.2     FINANCIALS
      • 8.7.3     PRODUCT PORTFOLIO
      • 8.7.4     KEY DEVELOPMENTS
      • 8.7.5     BUSINESS STRATEGY
      • 8.7.6     SWOT ANALYSIS
    • 8.8     NOVARTIS AG
      • 8.8.1     OVERVIEW
      • 8.8.2     FINANCIALS
      • 8.8.3     PRODUCT PORTFOLIO
      • 8.8.4     KEY DEVELOPMENTS
      • 8.8.5     BUSINESS STRATEGY
      • 8.8.6     SWOT ANALYSIS
    • 8.9     PFIZER, INC.
      • 8.9.1     OVERVIEW
      • 8.9.2     FINANCIALS
      • 8.9.3     PRODUCT PORTFOLIO
      • 8.9.4     KEY DEVELOPMENTS
      • 8.9.5     BUSINESS STRATEGY
      • 8.9.6     SWOT ANALYSIS
    • 8.10     ROCHE
      • 8.10.1     OVERVIEW
      • 8.10.2     FINANCIALS
      • 8.10.3     PRODUCT PORTFOLIO
      • 8.10.4     KEY DEVELOPMENTS
      • 8.10.5     BUSINESS STRATEGY
      • 8.10.6     SWOT ANALYSIS

LIST OF TABLES

      • TABLE 1     IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 2     IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2013-2021) ($MN)
      • TABLE 3     MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 4     THERAPEUTIC VACCINES GLOBAL MAREKT REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 5     CHECKPOINT INHIBITORS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 6     NON-SPECIFIC IMMUNOTHERAPY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 7     IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN)
      • TABLE 8     ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 9     TOP SELLING DRUGS IN ONCOLOGY SEGMENT OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
      • TABLE 10     INFLAMMATION GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 11     TOP SELLING DRUGS IN INFLAMMATION OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
      • TABLE 12     CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 13     TOP SELLING DRUGS IN CNS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
      • TABLE 14     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • TABLE 15     TOP SELLING DRUGS IN OTHERS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
      • TABLE 16     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2014-2015)
      • TABLE 17     APPROVALS, (2014-2015)
      • TABLE 18     MERGERS AND ACQUISITIONS, (2014-2015)
      • TABLE 19     OTHER DEVELOPMENTS (2015)
      • TABLE 20     ABBVIE, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 21     ABBVIE, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
      • TABLE 22     ABBVIE, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 23     AMGEN, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 24     AMGEN, INC.: TOTAL REVENUE, BY PRODUCT TYPE, (2012-2014) ($MN)
      • TABLE 25     AMGEN, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 26     BIOGEN: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 27     BIOGEN: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 28     BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 29     BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY PRODUCT, (2012-2014) ($MN)
      • TABLE 30     BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 31     CELGENE: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 32     CELGENE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 33     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 34     JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
      • TABLE 35     JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 36     MERCK & CO., INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 37     MERCK & CO., INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
      • TABLE 38     MERCK & CO., INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 39     NOVARTIS AG: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 40     NOVARTIS AG: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
      • TABLE 41     NOVARTIS AG: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 42     PFIZER, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 43     PFIZER, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
      • TABLE 44     PFIZER, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 45     ROCHE: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 46     ROCHE: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
      • TABLE 47     ROCHE: PHARMACEUTICALS REVENUE, BY APPLICATION, (2012-2014) ($MN)
      • TABLE 48     ROCHE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)

LIST OF FIGURES

      • FIGURE 1     IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE, BY REGION, (2013-2021) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: IMMUNOTHERAPEUTICS MARKET
      • FIGURE 3     IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     IMMUNOTHERAPEUTICS MARKET: FORECASTING MODEL
      • FIGURE 5     IMMUNOTHERAPEUTICS MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION
      • FIGURE 6     IMMUNOTHERAPEUTICS GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     IMMUNOTHERAPEUTICS MARKET: PORTER'S ANALYSIS
      • FIGURE 9     IMMUNOTHERAPEUTICS MARKET: PATENT FILLING BY MAJOR PLAYERS, (2011-2015)
      • FIGURE 10     IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014
      • FIGURE 11     IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2014 V'S 2021) ($MN)
      • FIGURE 12     IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2014 V'S 2021) ($MN)
      • FIGURE 13     IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN)
      • FIGURE 14     KEY GROWTH STRATEGIES, (2014-2015)
      • FIGURE 15     SWOT: ABBVIE, INC.
      • FIGURE 16     SWOT: AMGEN, INC.
      • FIGURE 17     SWOT: BIOGEN
      • FIGURE 18     SWOT: BRISTOL-MYERS SQUIBB
      • FIGURE 19     SWOT: CELGENE
      • FIGURE 20     SWOT: JOHNSON & JOHNSON
      • FIGURE 21     SWOT: MERCK & CO., INC.
      • FIGURE 22     SWOT: NOVARTIS AG
      • FIGURE 23     SWOT: PFIZER, INC.
      • FIGURE 24     SWOT: ROCHE